AstraZeneca begins phase III evaluation of platinum anticancer agent; milestone triggered April 6, 2001
First-in-class indolocarbazole anticancer agent introduced by BMS at ACS and AACR meetings April 6, 2001
Integrin antagonists as orally active tumor angiogenesis inhibitors subject of ACS presentation April 6, 2001
RSS